Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Robert Charles BreedlovePrincipal Accounting Officer | Phathom PharmaceuticalsPHAT | Open-market sale | 25/11/03 | 25/11/05 | 524 sh | $13.51 | $7,079.24 | −1.1% |
Robert Charles BreedlovePrincipal Accounting Officer | Phathom PharmaceuticalsPHAT | Open-market sale | 25/09/05 | 25/09/09 | 461 sh | $12.09 | $5,573.49 | −1.0% |
Robert Charles BreedlovePrincipal Accounting Officer | Phathom PharmaceuticalsPHAT | Open-market sale | 25/07/16 | 25/07/18 | 1,692 sh | $8.36 | $14,145.12 | −3.4% |
James N. TopperDirector | Phathom PharmaceuticalsPHAT | Open-market buy | 25/05/21 | 25/05/23 | 3,780 sh | $3.86 | $14,590.8 | +6.8% |
Phathom PharmaceuticalsPHAT | Open-market buy | 25/05/13–25/05/14 | 25/05/15 | 7,420 sh2 trades | $3.30avg. | $24,455.2 | +15.4% | |
Phathom PharmaceuticalsPHAT | Open-market buy | 25/05/09–25/05/12 | 25/05/13 | 48,203 sh3 trades | $3.17avg. | $152,834.6 | No record | |
Phathom PharmaceuticalsPHAT | Open-market buy | 25/05/06–25/05/07 | 25/05/08 | 10,000 sh2 trades | $2.50avg. | $25,000 | +11.7% | |
Molly HendersonCFO and CBO | Phathom PharmaceuticalsPHAT | Open-market sale | 25/04/07 | 25/04/08 | 3,678 sh | $4.55 | $16,734.9 | −3.9% |
Asit ParikhDirector | Phathom PharmaceuticalsPHAT | Open-market buy | 25/03/13 | 25/03/17 | 10,000 sh | $4.42 | $44,200 | +13.2% |
Molly HendersonCFO and CBO | Phathom PharmaceuticalsPHAT | Open-market sale | 25/01/21 | 25/01/23 | 6,583 sh | $6.59 | $43,381.97 | −6.6% |
Terrie CurranPresident and Chief Executive | Phathom PharmaceuticalsPHAT | Open-market sale | 25/01/21 | 25/01/23 | 19,109 sh | $6.59 | $125,928.31 | −5.0% |
Azmi NabulsiCOO | Phathom PharmaceuticalsPHAT | Open-market sale | 25/01/21 | 25/01/23 | 7,886 sh | $6.59 | $51,968.74 | −3.3% |
Molly HendersonCFO and CBO | Phathom PharmaceuticalsPHAT | Open-market sale | 24/12/19 | 24/12/20 | 1,291 sh | $8.00 | $10,328 | −1.3% |
Azmi NabulsiCOO | Phathom PharmaceuticalsPHAT | Open-market sale | 24/12/19 | 24/12/20 | 1,118 sh | $8.00 | $8,944 | −0.5% |
Frank KarbeDirector | Phathom PharmaceuticalsPHAT | Open-market buy | 24/12/13 | 24/12/16 | 12,500 sh | $7.93 | $99,125 | +28.1% |
Asit ParikhDirector | Phathom PharmaceuticalsPHAT | Open-market buy | 24/12/13 | 24/12/16 | 10,000 sh | $8.12 | $81,200 | +15.3% |
Molly HendersonCFO and CBO | Phathom PharmaceuticalsPHAT | Open-market sale | 24/07/15 | 24/07/17 | 4,325 sh | $11.72 | $50,689 | −4.2% |
Terrie CurranPresident and Chief Executive | Phathom PharmaceuticalsPHAT | Open-market sale | 24/07/15 | 24/07/17 | 33,848 sh | $11.72 | $396,698.56 | −8.2% |
Azmi NabulsiCOO | Phathom PharmaceuticalsPHAT | Open-market sale | 24/07/15 | 24/07/17 | 10,901 sh | $11.72 | $127,759.72 | −4.3% |
Molly HendersonCFO and CBO | Phathom PharmaceuticalsPHAT | Open-market sale | 24/04/08 | 24/04/10 | 3,435 sh | $11.10 | $38,128.5 | −3.5% |